Evonik evaluates all substances placed on the market (> 1 metric ton p.a.). To ensure a sound basis for risk assessment, we also take into account small quantities of SoCs. Where necessary, restrictions are placed on certain usage patterns or, in extreme cases, a complete ban is issued on use in certain products. Evonik evaluates its substances using its own chemicals management system (CMS). This system lets us evaluate our substances at global level. The content of the CMS has been harmonized with the requirements of ICCA and REACH. We employ advanced technologies and implement various risk management actions to ensure safe production and use.
CHEMICALS MANAGEMENT SYSTEMPLUS
As an extension of the CMS, our Chemicals Management SystemPLUS is used for products containing more than 0.1 percent of a substance that meets SVHC criteria. Our aim is to reduce or replace these wherever possible.
TARGET
- Include and evaluate substances/products from acquisitions in CMS/CMSPLUS by the end of 2029
CMS/CMSPLUS
During the reporting period, we continued our efforts to include and evaluate our substances and products in CMS/CMSPLUS. To this end, we assessed our products with the highest content of SVHCs (and SoCs where possible), creating the basis for further activities in respect of CMSPLUS. These include improving manufacturing processes or replacing SVHCs by developing and using alternative substances.
Process development: Linking CMSPLUS and PSA
In the reporting year, we began the work of systematically linking our CMSPLUS and business sustainability analysis processes. The aim is to combine the findings yielded by both processes so that we can develop more targeted actions, including specific implementation schedules. With this holistic approach, we are enhancing our ability to detect risks at an early stage and effectively minimize them.